Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.
Shanghai Junshi Biosciences Co., Ltd. has announced the approval of their supplemental new drug application for toripalimab for advanced triple-negative breast cancer (TNBC) therapy, marking it the 10th indication approved in China. This follows positive results from the TORCHLIGHT Phase III study showing significantly improved progression-free survival for patients. Toripalimab, the first domestic anti-PD-1 monoclonal antibody approved in China, is now included in six indications on the National Reimbursement Drug List.
For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.
